Cell and gene therapy CDMO market seen reaching $21.35 billion by 2030

The Business Research Company projects rapid expansion in the cell and gene therapy contract development and manufacturing organization market, with demand rising as cancer rates, biotech outsourcing and advanced therapy pipelines grow. The market is forecast to nearly triple from 2025 levels by 2030, led by North America and faster growth in Asia-Pacific.

Why it matters: - Cell and gene therapy CDMOs are becoming more central to how advanced therapies move from research into commercial production. - Rising cancer incidence is adding pressure for specialized manufacturing capacity and targeted therapy development. - The market is expanding quickly, signaling more outsourcing across biotech and broader demand for end-to-end development support.

What happened: - The Business Research Company released its Cell and Gene Therapy Contract Development Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 11, 2026. - The report projects the cell and gene therapy CDMO market will grow from $6.92 billion in 2025 to $8.85 billion in 2026. - The report forecasts the market will reach $21.35 billion by 2030. - The company also says the market will grow at a 27.8% CAGR in 2026 and a 24.6% CAGR from 2026 to 2030. - The report includes a free sample and a full version online: More information and the full report.

The details: - Cell and gene therapy CDMOs support development, manufacturing and commercialization of advanced cell and gene therapy products. - The report says these organizations work with biopharmaceutical firms, academic institutions and government agencies. - The market’s growth drivers include biotech firms outsourcing advanced therapy manufacturing, limited internal development capacity, more early-stage biotech companies, expanding orphan drug pipelines and demand for specialized production expertise. - Future growth is expected to be supported by commercialization of gene-modified therapies, flexible manufacturing capacity, broader global CDMO collaborations, higher investment in cell therapy pipelines and more regulatory approvals. - The report highlights emerging trends including end-to-end CDMO services, commercial-scale manufacturing support, advanced gene editing technologies, faster development timelines and stronger regulatory support. - The report says cancer remains a key demand driver because CDMOs help develop and manufacture targeted treatments that can improve effectiveness and patient outcomes. - In Australia, the Australian Institute of Health and Welfare reported about 165,000 new cancer diagnoses in 2023, or more than 450 per day, with males making up about 55% of cases. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

Between the lines: - The forecast suggests cell and gene therapy manufacturing is shifting from a niche capability toward a more scaled industrial service line. - The emphasis on commercial-scale support and regulatory integration points to a market preparing for broader therapy approval and rollout. - Regional growth outside North America suggests more capacity buildout and biopharma activity are moving closer to emerging demand centers. - The report’s added tools, including TAM analysis, company scoring matrices and dashboards, indicate buyers want more decision-support data around where to invest and partner.

What's next: - The market is expected to keep expanding as more gene-modified and cell therapy programs move toward commercialization. - CDMOs are likely to compete more on speed, scale, regulatory support and integrated service offerings. - Asia-Pacific may narrow the gap with North America as investment and healthcare demand increase. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics and future-trend analysis.

The bottom line: - Cell and gene therapy CDMOs are moving into a fast-growth phase as cancer demand, outsourcing and advanced therapy pipelines push the market toward $21.35 billion by 2030.